Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Hepatitis A Inactivated & Hepatitis B Articles

FDA approves accelerated dosing schedule for GSK's Twinrix

9 April 2007

Sinovac's Bileve cleared by China's FDA

17 January 2005

GSK's TwinRix cleared in EU for rapid use

19 September 2001

GSK's Twinrix approved by FDA

17 May 2001

SmithKline Beecham sales for 3rd quarter meet estimates, Avandia setback

21 October 1999

Currency impact lifts SmithKline Beecham

20 April 1999

SmithKline Beecham Ground-Breaking In China

16 November 1998

Medeva Files For European Approval Of Hepagene

27 October 1998

GW-SB Merger Will Create R&D Superpower

5 February 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

Twinrix Pediatric Debuts In UK; 1st Approval For Infanrix Hep B

5 August 1997

Upbeat UK Companies At Goldman Sachs Conference

17 June 1997

SB's Twinrix Pediatric Approved In EU

24 February 1997

SB's Twinrix Launched In Its First Market

20 January 1997

SmithKline Beecham 3rd Qtr Earnings Leap 20%

28 October 1996

EU CPMP October Meeting

28 October 1996

SB's Twinrix Backed by CPMP

7 October 1996

EUROPEAN AND LONDON STOCK COMMENT

30 September 1996

Vaccines Business Set For Explosive Growth, Says SB

20 May 1996

SmithKline Beecham Unveils Power Pipeline

9 October 1995

Showing 1-20 of 20 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS